Effects of platelet factor 4 on expression of bone marrow heparan sulfate in syngenic bone marrow transplantation mice

Abstract

To explore the effects of platelet factor 4 (PF4) on hematopoietic reconstitution and its mechanism in syngenic bone marrow transplanation (BMT). The syngenic BMT mice models were established. 20 and 26 h before irradiation, the mice were injected 20 μg/kg PF4 or PBS twice into abdominal cavity, then the donor bone marrow nuclear cells (BMNC) were transplanted. On the 7th day, spleen clone forming units (CFU-S) were counted. On the 7th, 14th and 21st day after BMT, the BMNC and megakaryoryocytes in bone marrow tissue were counted and the percentage of hematopoietic tissue and expression level of heparan sulfate in bone marrow tissue were assessed. In PF4-treated groups, the CFU-S counts on the 7th day were higher than those in BMT groups after BMT. The BMNC and megakaryoryocyte counts and the percentage of hematopoietic tissue and heparan sulfate expression level were higher than those in BMT group on the 7th, 14th and 21st day after BMT (P<0.01 orP<0.05). PF4 could accelerate hematopoietic reconstitution of syngenic bone marrow transplantation. The promotion of the heparan sulfate expression in bone marrow may be one of mechanisms of PF4.

Keywords

platelet factor 4 / bone marrow transplantation / heparan sulfate

References

[1] XiX, CaenJ P, FournierS, et al.. Direct and reversible inhibition of platelet factor 4 on megakaryocyte development from CD34⁺ cord blood cells: comparative studies with transforming growth factor beta1. Br J Haematol, 2002, 93(2): 265-265

[2] HanZ C, LuM, LiJ, et al.. Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents. Blood, 1997, 89(7): 2328-2328

[3] CaenJ P, XiX, AidoudiS, et al.. Platelet factor 4, reversible inhibitor of megakaryocytogenesis, protector of megakaryocytes during chemotherapy. Bull Acad Natl Med, 1995, 179(8): 1657-1657

[4] PerrimonN, BernfieldM. Specificities of heparan sulphate proteoglycans in developmental processes. Nature, 2000, 404(6779): 725-725

[5] GuptaP, OegemaT R, BraizilJ J, et al.. Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. Blood, 1998, 92(12): 4641-4641

[6] HanZ C, BellucciS, ShenZ X, et al.. Glycosaminoglycans enhance megakaryocytopoiesis by modifying the activities of hematopoietic growth regulators. J Cell Physiol, 2002, 168(1): 97-97

[7] GuptaP, OegemaT R, BrazilJ J, et al.. Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates: requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins. Blood, 2000, 95(1): 147-147